- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00484926
Association of Clopidogrel Therapy and Stent Thrombosis (REAL-LATE)
August 9, 2012 updated by: Seung-Jung Park
Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events
The purpose of REAL-LATE (Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events) trial is to assess the relationship between clopidogrel use and long-term rates of cardiac death or MI after DES implantation in real-world practice and to estimate the duration of dual antiplatelet therapy for preventing the late thrombotic events.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
An observational analysis from BASKET-LATE (Basel Stent Kosten-Effekivitats Trial-Late Thrombotic Events) examined the incidence of clinical events after cessation of clopidogrel therapy.
This study identified 746 patients who were without major adverse events 6 months after drug-eluting or bare-metal stent placement.
All patients had stopped taking clopidogrel and were followed up for an additional 12 months.
At 18-month follow-up, there was no difference between patients with a drug-eluting or bare-metal stent in cumulative rates of death or myocardial infarction (MI).
However, after clopidogrel discontinuation patients receiving drug-eluting vs bare-metal stents experienced higher rates of death and MI (4.9% vs 1.3%, respectively).
These results have created uncertainty regarding the minimal necessary duration of antiplatelet therapy after drug-eluting stent implantation.
Also, there remains widespread uncertainty regarding the risk of clinical events after the discontinuation of clopidogrel, particularly after DES implantation.
Study Type
Interventional
Enrollment (Actual)
2000
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bucheon, Korea, Republic of
- Soonchunhyang University Bucheon Hospital
-
Choeng Ju, Korea, Republic of
- Choeng Ju St.Mary's Hospital
-
Chuncheon, Korea, Republic of
- Kangwon National University Hospital
-
Daejeon, Korea, Republic of
- Chungnam National University Hospital
-
GangNeung, Korea, Republic of
- Asan Medical Center
-
Gyongju, Korea, Republic of
- DongGuk University Gyongju Hospital
-
Jeonju, Korea, Republic of
- Chonbuk National University Hospital
-
Kwangju, Korea, Republic of
- Kwangju Christian Hospital
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
Seoul, Korea, Republic of
- Hangang Sacred Heart Hospital
-
Seoul, Korea, Republic of
- Seoul Veterans Hospital
-
Seoul, Korea, Republic of
- Kyungsang University Hospital
-
Ulsan, Korea, Republic of
- Ulsan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Among consecutive patients treated with DES, event-free patients who survived at least the first 12 months without nonfatal MI or repeat revascularization
- The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
Exclusion Criteria:
- Contraindication to antiplatelet therapy (aspirin or clopidogrel)
- Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
- Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
- Concurrent bleeding diathesis or major bleeding history requiring discontinuation of antiplatelet drugs.
- Patients with left main stem stenosis (>50% by visual estimate) or left main stenting
- Concomitant disease requiring long-term use of clopidogrel (stroke, peripheral vascular disease, significant carotid a. disease, etc)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aspirin
Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
|
stopping clopidogrel at 1 year after DES
|
Experimental: Aspirin,Clopidogrel
Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
|
continue aspirin and clopidogrel 1year after DES
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The composite of cardiac death or MI in the intent-to-treat population
Time Frame: 1 year after randomization
|
1 year after randomization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All death
Time Frame: 1 year after randomization
|
1 year after randomization
|
Myocardial infarction
Time Frame: 1 year after randomization
|
1 year after randomization
|
Stroke
Time Frame: 1 year after randomization
|
1 year after randomization
|
Stent Thrombosis
Time Frame: 1 year after randomization
|
1 year after randomization
|
Bleeding events
Time Frame: 1 year after randomization
|
1 year after randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
March 1, 2010
Study Registration Dates
First Submitted
June 11, 2007
First Submitted That Met QC Criteria
June 11, 2007
First Posted (Estimate)
June 12, 2007
Study Record Updates
Last Update Posted (Estimate)
August 10, 2012
Last Update Submitted That Met QC Criteria
August 9, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Clopidogrel
Other Study ID Numbers
- 20070186
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruitingLeft Main Coronary Artery StenosisSwitzerland
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on Aspirin monotherapy
-
St. Antonius HospitalCompletedMyocardial Infarction | Stroke | Bleeding | Aortic Valve DiseaseNetherlands, Belgium, Czechia, Luxembourg
-
Shenyang Northern HospitalChanghai Hospital; ANKON medical technologies (Shanghai)Co.,LTDCompletedIschemic Heart Disease | Gastrointestinal InjuryChina
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
Masonic Cancer Center, University of MinnesotaActive, not recruiting
-
Peking Union Medical College HospitalCompletedChronic Periaortitis | Tocilizumab MonotherapyChina
-
Xizang Haisco Pharmaceutical Co., LtdRecruiting
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
-
Second Affiliated Hospital of Guangzhou Medical...Not yet recruitingNon-small Cell Lung Cancer
-
Zai Lab (Shanghai) Co., Ltd.Completed
-
Seoul National University HospitalThreshold PharmaceuticalsCompletedBiliary Tract CancerKorea, Republic of